Concord Biotech Limited (CONCORDBIO) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Concord Biotech is a leading fermentation-based API manufacturer that is currently scaling its formulations and CDMO businesses to drive a rebound in growth. Investors will be focused on whether the company can maintain its margin trajectory and successfully ramp up new injectable product launches following a challenging fiscal year.

Concord Biotech Limited Q1 Results Date and Time

The board meeting is scheduled for July 31, 2026, to consider the unaudited standalone and consolidated financial results for the Q1 ended June 30, 2026.

The earnings conference call is scheduled for August 3, 2026, at 3:30 PM IST with participation from the Chairman, MD, and CFO.

What to expect from Concord Biotech Limited's Q1 FY27 results

Concord Biotech is positioned for a strong revenue rebound in Q1 FY27, supported by a 13-14% year-on-year rupee depreciation that provides a significant translation tailwind for its 45% export-denominated revenue. The company's core API business is expected to benefit from broader sector-wide growth, which saw median peer revenue rise 15.4% YoY in the first quarter. Management has guided for FY27 growth to exceed the historical 18% average, a target now bolstered by recent USFDA approvals for Tofacitinib and Mycophenolate Mofetil. Reported EBITDA margins are likely to improve sequentially from the 30.1% level seen in Q1 FY26, as the combined drag from injectable facility losses and Stellon Biotech setup costs continues to narrow. The upcoming call will likely focus on the initial revenue contribution from these new growth drivers and the progress of inventory normalization expected by the end of H1 FY27.

Key Things To Watch

Performance vs Guidance Tracking: Tracking progress against management's medium-term growth and margin goals.

• Consolidated revenue growth — 18%+ for FY27 — status pending Q1 results
• EBITDA margin — 37-41% (adjusted) — status consistent with FY26 run-rate

Injectable facility and Stellon Biotech ramp-up: Monitoring the transition from cost-heavy setup to revenue-generating operations.

• Injectable facility losses — ~Rs. 10–12 Cr per quarter in Q3 FY26 — monitoring for sequential decline
• Stellon Biotech US subsidiary — licenses obtained; tracking commencement of sales in H1 FY27

New product monetization: Execution of US market entry strategy for recently approved products.

• Tofacitinib Tablets (5 mg & 10 mg) — US market size ~US$500 Mn — tracking initial launch revenue
• Mycophenolate Mofetil Oral Suspension — US market size ~US$30 Mn — monitoring market entry strategy

Operating metric trajectory: Key indicators of operational efficiency and inventory management.

• Inventory normalization — Rs. 326.4 Cr as of March 31, 2026 — management guided normalization within H1 FY27
• Power costs — 1–1.5% reduction target — tracking progress via FSGE Renewable captive plant investment

Risks and headwinds to monitor: External factors influencing business operations.

• US tariff environment — 200% generic tariff window includes 2-year zero-tariff period — monitoring impact on CDMO discussions
• Immunosuppressant concentration — 70–75% of API sales — monitoring medium-term dependency